Dalazatide

Drug Profile

Dalazatide

Alternative Names: Debio-0824; ShK-186

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Airmid; University of California at Irvine
  • Developer Kineta; KPI Therapeutics; Seattle Childrens Research Institute; University of California at Irvine; University of Groningen
  • Class Amides; Peptides; Proteins
  • Mechanism of Action Kv1.3 potassium channel inhibitors; T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inclusion body myositis; Vasculitis
  • Research Inflammatory bowel diseases; Multiple sclerosis
  • No development reported Autoimmune disorders; Lupus nephritis; Obesity; Plaque psoriasis; Psoriatic arthritis

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Lupus-nephritis in USA (SC, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Plaque-psoriasis in USA (SC, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Psoriatic-arthritis(Treatment-experienced) in USA (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top